# Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Combination Therapy and High-dose Rosuvastatin Monotherapy in Patients With Minimal to Intermediate Coronary Artery Disease Without Percutaneous Coronary Intervention

Study · id `cardio:ct-nct06186037` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06186037](<https://clinicaltrials.gov/study/NCT06186037>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06186037

Browse, organ or system: Heart; Metabolism  
Browse, condition area: Risk and prevention; Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 6356 participants.

## Technical summary

Registry record NCT06186037. Randomized; no masking; primary purpose treatment. Start 2024-02-01 (actual); primary completion 2029-02-28 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 6356 participants (planned count; ClinicalTrials.gov record NCT06186037, source copy `cardio:ctgov-nct06186037-2025-06-25`, retrieved 2026-10-26)
- Started: 2024-02-01 (actual) (ClinicalTrials.gov record NCT06186037, source copy `cardio:ctgov-nct06186037-2025-06-25`, retrieved 2026-10-26)
- Primary completion: 2029-02-28 (anticipated) (ClinicalTrials.gov record NCT06186037, source copy `cardio:ctgov-nct06186037-2025-06-25`, retrieved 2026-10-26)
- Completion: 2029-02-28 (anticipated) (ClinicalTrials.gov record NCT06186037, source copy `cardio:ctgov-nct06186037-2025-06-25`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT06186037, source copy `cardio:ctgov-nct06186037-2025-06-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06186037-2025-06-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Combination Therapy and High-dose Rosuvastatin Monotherapy in Patients With Minimal to Intermediate Coronary Artery Disease Without Percutaneous Coronary Intervention
- Acronym: ALMIGHTY
- Condition: Coronary Artery Disease
- Condition: Dyslipidemias
- Condition: Primary Prevention
- Intervention (Drug): Combination drug group of Ezetimibe 10 mg/Rosuvastatin 5 mg
- Intervention (Drug): Mono drug group of Rosuvastatin 20 mg
- Lead sponsor: Saint Vincent's Hospital, Korea
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: Saint Vincent's Hospital, Korea (`cardio:org-saint-vincent-s-hospital-korea`)

## Provenance

Content hash: 1ca824f26daedd4b7200357be1de61dad70b5927b7b3486fea701580ba075e90
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
